Free preview
MD Pharmacology NMC syllabus ~5 min read Recent advances last updated on 2026-06-18

Antiretroviral Drugs

Drug Classes, HIV Replication Targets, HAART, Resistance & Prophylaxis

Past RGUHS + DNB + MPMSU + MUHS + VNSGU · 32 RGUHSSep '25 RGUHSMay '25 DNBDec '25 RGUHSJun '24 RGUHSDec '23 RGUHSJul '23 DNBOct '23 VNSGUJun '23 RGUHSNov '22 RGUHSJul '21 MUHSWinter '21 VNSGUJun '21 RGUHSNov '20 RGUHSJun '20 RGUHSMay '18 RGUHSNov '17 MUHSSummer '17 Suppl VNSGUMay '17 RGUHSJun '16 VNSGUApr '16 MPMSU2015 DNBDec '15 MUHSWinter '15 DNBDec '14 RGUHSMay '11 RGUHSMay '11 RGUHSMay '10 RGUHSMay '09 MPMSU2009 MPMSU2007 RGUHSSep '06 RGUHSSep '06

Introduction

  • Antiretroviral (ARV) drugs are agents active against HIV, a lentivirus (retrovirus subfamily). They suppress replication and prolong life but do not cure — because the HIV genome integrates into host DNA, eradication is impossible with current agents.
  • Goal of therapy — maximal, durable suppression of plasma HIV-RNA to undetectable (<20–50 copies/mL) with a rise in CD4 count; the deeper the suppression, the lower the risk of resistance. With early, adherent ART, life expectancy approaches that of an uninfected person.
  • Treatment is lifelong, complex and adherence-critical; combination therapy (≥3 drugs from ≥2 classes) is mandatory — monotherapy is contraindicated.
  • Two species — HIV-1 (global epidemic) and HIV-2 (West Africa, less virulent). Most ARVs cover both except NNRTIs and enfuvirtide, which are HIV-1-specific.
Continue reading

Antiretroviral Drugs

PharmaNotes Pro · LAQ

Sign in with your Google account. If you're already subscribed, the chapter unlocks immediately — otherwise, pick Monthly or Annual on the next step.